Compare Repligen Corporation Common Stock (RGEN) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Walmart Stores Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Walmart Stores Inc trades at $117.79 (market cap $890.80B). The key difference: Walmart Stores Inc is far larger — about 80× Repligen Corporation Common Stock's market cap, and Walmart Stores Inc pays a 0.88% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Walmart Stores Inc for 101 Days on average.
| RGEN | WMT | |
|---|---|---|
Market Cap | $11.14B | $890.80B |
Volume | 1,259,263 | 17,493,315 |
Sector | Health | Consumer Staples |
52-Week High | $194.57 | $134.20 |
52-Week Low | $102.87 | $100.61 |
Typical Hold Time | 0 Days | 101 Days |
Enterprise Value | $11.02B | $953.03B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Walmart (WMT) trades at $113.08, up 1.55% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $680.99B in 2025, with net income reaching $19.44B, and the company has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion in AI capabilities, e-commerce growth exceeding 50%, and a new Medicare Advantage partnership, signaling strategic initiatives to bolster market share.
The outlook for WMT is positive, supported by robust earnings growth, analyst consensus favoring buys (71%), and a price target of $128.84 implying ~14% upside. Key risks include elevated valuation multiples (P/E 40.68) and rising operational costs, but the company's scale and digital investments provide a competitive edge. Investors should weigh growth prospects against cost pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
